Weight gain during menopause is a common challenge for millions of women worldwide. Hormonal changes can make it harder to maintain a healthy weight, even for those who follow balanced diets and exercise regularly. Recent clinical trial findings suggest that a new oral GLP-1 medication, Foundayo (orforglipron), may offer an effective option for women seeking long-term weight management during this important stage of life.
New data presented at the American Diabetes Association's 86th Scientific Sessions revealed that women with obesity or overweight experienced meaningful weight loss with Foundayo, regardless of whether they were premenopausal, perimenopausal, or postmenopausal. The analysis was based on results from the Phase 3 ATTAIN-1 and ATTAIN-2 clinical trials involving more than 1,500 female participants.
Menopause is associated with significant hormonal fluctuations that can influence body composition, metabolism, and fat distribution. Many women notice increased abdominal fat accumulation during midlife, even when their eating and exercise habits remain unchanged.
Health experts have long recognized that menopause-related weight gain can increase the risk of several conditions, including:
Despite the widespread impact of menopause on body weight, relatively few obesity treatment studies have specifically examined outcomes based on menopausal status. This new analysis helps address that gap by evaluating how women at different stages of menopause respond to a modern weight management therapy.
Foundayo, also known as orforglipron, is an oral GLP-1 receptor agonist approved for chronic weight management in adults with obesity and certain adults who are overweight with weight-related medical conditions.
Unlike some injectable GLP-1 medications, Foundayo is taken as a once-daily pill. One of its distinguishing features is that it can be taken without food or water restrictions, making it a potentially convenient option for patients seeking a simpler treatment routine.
Researchers are also investigating the medication for additional health conditions, including type 2 diabetes, obstructive sleep apnea, hypertension, osteoarthritis-related knee pain, peripheral artery disease, and stress urinary incontinence.
The newly presented analysis evaluated women receiving the highest maintenance dose of Foundayo during two large Phase 3 studies.
ATTAIN-1 included adults with obesity or overweight who did not have diabetes. After 72 weeks of treatment, women experienced notable reductions in body weight across all stages of menopause.
Among women taking the highest dose:
Many participants also achieved substantial weight-loss milestones. More than 80% of women lost at least 5% of their body weight, while a significant percentage achieved reductions of 15% or more.
ATTAIN-2 focused on adults with obesity or overweight who also had type 2 diabetes. Weight management is often more difficult in this population, making the findings especially noteworthy.
Women taking the highest dose experienced:
Despite the added challenges associated with diabetes, participants still achieved meaningful improvements in body weight and overall health indicators.
Beyond total weight loss, researchers observed significant reductions in waist circumference. This measurement is particularly important because excess abdominal fat is closely linked to cardiometabolic risk.
Women in the trials experienced waist circumference reductions ranging from approximately 3 to 5 inches, depending on menopausal status and study group.
Reducing abdominal fat may contribute to improved metabolic health and lower risk factors associated with cardiovascular disease and diabetes.
For many women, menopause represents a period when weight management becomes increasingly difficult despite continued lifestyle efforts. Hormonal changes can alter metabolism and fat storage patterns, making traditional approaches less effective.
The new findings suggest that Foundayo may provide consistent benefits across multiple menopausal stages. Researchers reported meaningful weight reduction among premenopausal, perimenopausal, and postmenopausal participants, indicating that the therapy's effectiveness does not appear to be limited by menopausal status.
This information could help healthcare professionals make more informed treatment decisions for women struggling with obesity or excess weight during midlife.
GLP-1 receptor agonists have transformed the obesity treatment landscape in recent years. These medications work by mimicking natural hormones involved in appetite regulation and blood sugar control.
Benefits commonly associated with GLP-1 therapies include:
As research continues, oral formulations such as Foundayo may expand access to treatment by offering a convenient alternative to injectable options.
While the results are encouraging, ongoing research will continue to evaluate the long-term safety, effectiveness, and broader health benefits of orforglipron. Scientists are exploring its potential role in multiple chronic health conditions beyond obesity management.
The latest findings add to a growing body of evidence supporting GLP-1 therapies as an important tool in addressing obesity, particularly among populations that have historically faced unique weight management challenges.
For women navigating menopause-related weight gain, these results provide hope that effective treatment options are becoming increasingly available.
The latest post-hoc analysis from the ATTAIN-1 and ATTAIN-2 clinical trials demonstrated that Foundayo was associated with significant weight loss in women across all stages of menopause. Participants achieved meaningful reductions in body weight and waist circumference, including women living with type 2 diabetes.
As obesity treatment continues to evolve, these findings highlight the potential of oral GLP-1 therapies to support women during one of the most challenging periods for weight management. Although individual results may vary, the research represents an important step forward in understanding how modern obesity medications perform in menopausal populations.
Eli Lilly and Company regarding Foundayo (orforglipron), the ATTAIN-1 and ATTAIN-2 studies.
This article is intended for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Readers should consult a qualified healthcare professional before making any decisions regarding weight management, medications, or other health-related concerns. Individual results may vary, and ongoing research may provide additional information about the safety and effectiveness of the therapies discussed.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.